CN1220168A - Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form - Google Patents

Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form Download PDF

Info

Publication number
CN1220168A
CN1220168A CN 98125670 CN98125670A CN1220168A CN 1220168 A CN1220168 A CN 1220168A CN 98125670 CN98125670 CN 98125670 CN 98125670 A CN98125670 A CN 98125670A CN 1220168 A CN1220168 A CN 1220168A
Authority
CN
China
Prior art keywords
bone morphogenetic
hydroxyapatite
morphogenetic protein
dosage form
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 98125670
Other languages
Chinese (zh)
Other versions
CN1087633C (en
Inventor
孙箭华
李晓光
孙福玉
孟庆恩
周蕙
刘鼎新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Iron and Steel Research Institute
Original Assignee
Central Iron and Steel Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Iron and Steel Research Institute filed Critical Central Iron and Steel Research Institute
Priority to CN98125670A priority Critical patent/CN1087633C/en
Publication of CN1220168A publication Critical patent/CN1220168A/en
Application granted granted Critical
Publication of CN1087633C publication Critical patent/CN1087633C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Materials For Medical Uses (AREA)

Abstract

The present invention belongs to the field of biomedical material, mainly is applicable to preparation of bone morphogenetic protein and hydroxyapatite compounded dosage form. Its preparation method includes the following steps:firstly, dissolving the bone morphogenetic protein in urea containing phosphoric acid buffer solution, then adding the hydroxyapatite in the above-mentioned material, then adding ethyl alcohol to separate out bone morphogenetic protein from urea solution and attach the bone morphogenetic protein to the surface of hydroxyapatite particles, then adopting the processes of centrifugal separation, cleaning and drying in the air so as to obtain the invented finished product.

Description

The manufacture method of bone morphogenetic protein and the compound dosage form of hydroxyapatite
The invention belongs to field of biomedical materials.Mainly be applicable to and produce bone morphogenetic protein and the compound dosage form of hydroxyapatite.
Bone morphogenetic protein (bone morphogenefic protein, be called for short BMP) be a kind of protein in body factor with unique induced osteogenesis function, in body osteanagenesis and repair process, bring into play pivotal role, knochenbruch is connect fast again, lack the quick Regeneration and Repair of bone, in the orthopaedics and the department of stomatology, have extensively and application prospect.
At present, preparation BMP has two kinds of methods: a kind of is to utilize biochemical extraction method directly to extract mixed type BMP from beast bone such as cattle, horse, pig, sheep, rabbit, Mus or osteosarcoma; Another kind is the people BMP that utilizes the synthetic unitary type of method of gene recombination.Gene recombinaton BMP lures bone or bone active strong, and is higher by 10 than the BMP of biochemical extraction method preparation 3-10 6Doubly.Though BMP has very strong induced osteogenesis activity, during implant into body, it is fast to absorb metabolism, and action time is short, is difficult to give full play to its induced osteogenesis effect; In addition, BMP does not have the support effect when reparation large scale bone is damaged.Therefore, BMP also needs with a certain carrier material compound when clinical practice, just so that himself obtain slow release and support.
Hydroxyapatite (Hydoxyapatite is called for short HA) is a kind of of calcium orthophosphate base bioceramic, and its chemical formula is Ca 10(PO 4) 6(OH) 2, it is the main inanimate matter that constitutes bone and tooth, behind the implant into body, can form chemical bonding with bone and soft tissue on its surface, has good biological activity and biocompatibility, is one of ideal carrier material of BMP.BMP and HA is compound, both helped giving full play to of BMP induced osteogenesis effect, the bone repair of hydroxyapatite is strengthened.
In the prior art, " material science and technology encyclopedia " 742-743 page or leaf has been reported calcium orthophosphate base bioceramic and bone morphogenetic protein compound material and preparation method thereof.Its preparation method is that BMP is dissolved in the guanidine hydrochloride of 4M, again the porous hydroxyapatite ceramic particle is placed the BMP guanidine hydrochloride solution, then mixture is dialysed with deionized water, eliminates guanidine hydrochloride; Mixture after the dialysis is drained through negative pressure in container, uses oxirane disinfection again after lyophilizing, and is standby.
This manufacture method is not introduced its technological process and corresponding technological parameter in detail, on the other hand, also there is following weak point in this method: i.e. the ionic strength height of guanidine hydrochloride, be difficult to make BMP to adsorb in hydroxyapatite surface, cause the BMP adsorption rate low, during this compound material implant into body, the BMP amount of bringing into is also few, and the good effect of BMP is not in full use.
The object of the present invention is to provide a kind of cost low, the relevant bone morphogenetic protein that carrier material absorption bone morphogenetic protein is high and the manufacture method of the compound dosage form of hydroxyapatite.
According to above-mentioned purpose, the present invention is that medium are realized the well compound of bone morphogenetic protein and hydroxyapatite with carbamide, and concrete skill step is as follows:
(1) bone morphogenetic protein is dissolved in the carbamide that contains phosphate buffer, forms the urea liquid that contains bone morphogenetic protein;
The concentration of phosphate buffer is 5-50mM, and acid-base value is PH6-8, and the concentration of carbamide is 5-8M.
The addition of phosphate buffer (volume ratio) is the 1-10% of urea amount,
The addition that bone morphogenetic protein adds in the carbamide is: 0.01-0.05mg/ml;
(2) granulous hydroxyapatite is added in the formed urea liquid that contains bone morphogenetic protein of above-mentioned steps, and after stirring under the 20-30 ℃ of temperature, left standstill 0.5-2 hour;
Addition in the adding bone morphogenetic protein urea liquid of hydroxyapatite is: 0.1-1.0g/ml;
Hydroxyapatite is a graininess, and its granularity is 50-500 μ m.
Stirring and leave standstill certain hour after the adding, is to make bone morphogenetic protein as much as possible all be adsorbed on the surface of hydroapatite particles, improves adsorption rate.
(3) ethanol is added in the formed urea liquid that contains hydroxyapatite and bone morphogenetic protein of above-mentioned technology, behind the mix homogeneously,, storE 0.5-2 hour, adopt centrifugal method subsequently, remove the liquid part in the solution, obtain precipitate at-60--80 ℃.It is the hydroxyapatite of surface adsorption bone morphogenetic protein.
Amount of alcohol added be urea liquid 1.5-3 doubly
Adding alcoholic acid purpose is for accelerated bone morphogenetic proteins separating out from urea liquid, adheres to then or is deposited on hydroxyapatite surface, further improves adsorption efficiency,
(4) with above-mentioned through centrifugalize gained precipitate temperature be 1-10 ℃, concentration is 85% alcoholic solution flushing 2-3 time, the reuse temperature is 1-10 ℃, the alcohol flushing of concentration 100% one time afterwards, and airing, aseptic preservation promptly becomes the compound dosage form of bone morphogenetic protein of the present invention and hydroxyapatite.
The ethanol of the concentration that twice usefulness is different washes precipitate, is to rinse out fully for the carbamide that will mix in the precipitate.Remaining then is the compound dosage form of pure bone morphogenetic protein and hydroxyapatite.
Compared with prior art, the present invention has following advantage:
1, behind the compound dosage form implant into body of prepared bone morphogenetic protein and hydroxyapatite, can make bone morphogenetic protein obtain effective slow release, the repair process of bone is accelerated.Experiment shows just had a large amount of new bones and cartilage to form in postoperative 7-21 days, and postoperative 21 visible ripe bones in back and bone marrow form.
2, carbamide is low from falling intensity, makes bone morphogenetic protein be easy to be adsorbed on the surface of hydroapatite particles, i.e. BMP adsorption efficiency height, and adsorbance is big, and the effect of BMP is given full play to.
Embodiment
Adopt manufacture method of the present invention, prepared three batches of bone morphogenetic proteins and the compound dosage form of hydroxyapatite.
At first a certain amount of bone morphogenetic protein is dissolved in the carbamide that contains phosphate buffer, the dosage and the concentration of the addition of bone morphogenetic protein, carbamide dosage and concentration, phosphate buffer are as shown in table 1.
Then add granulous hydroxyapatite in above-mentioned urea liquid, leave standstill certain hour at-60--80 ℃ after stirring, centrifugalize is partly separated the liquid in the solution, obtains precipitate.The granularity of hydroxyapatite, addition, whipping temp and time of repose are as shown in table 2.
Precipitate with gained washes twice with Different concentrations of alcohol at last, and airing, promptly obtains the compound dosage form of bone morphogenetic protein and hydroxyapatite.Wash used concentration of alcohol, flushing temperature, washing time is as shown in table 3.
Adopt the embodiment of the invention 1 prepared BMP to be used for the compound dosage form of HA, after cleaning,, sew up, promptly heal substantially after one month in bone damaged place filling this compound dosage form because the bone that bone cyst causes is damaged.Table 1 Embodiment B MP addition, urea concentration and dosage, phosphate buffer density and dosage
Figure A9812567000061
Table 2 embodiment hydroxyapatite granularity and addition, whipping temp and time of repose
Figure A9812567000062
Table 3 embodiment washes sedimentary concentration of alcohol and temperature
Figure A9812567000063

Claims (2)

1, the manufacture method of a kind of bone morphogenetic protein and the compound dosage form of hydroxyapatite is characterized in that this method comprises following processing step:
(1) bone morphogenetic protein is dissolved in the carbamide that contains phosphate buffer, forms and contain the bone morphogenetic protein urea liquid;
The concentration of phosphate buffer is 5-50mM, and acid-base value is PH6-8,
The concentration of carbamide is 4-9M,
The addition of phosphate buffer (volume ratio) is the 1-10% of urea amount,
The addition that bone morphogenetic protein adds in the carbamide is 0.01-0.05mg/ml;
(2) granulous hydroxyapatite is added in the formed urea liquid that contains bone morphogenetic protein of above-mentioned steps, and under 20-30 ℃ of temperature, stir, and left standstill 0.5-2 hour;
The addition of hydroxyapatite is carbamide: 0.1-1.0g/ml;
(3) ethanol is added in the formed urea liquid that contains hydroxyapatite and bone morphogenetic protein of above-mentioned technology, behind the mix homogeneously, storE 0.5-2 hour, adopt centrifugal method subsequently, remove the liquid part in the solution, obtain precipitate at-60--80 ℃.
The addition that its ethanol adds above-mentioned gained urea liquid is 1.5-3 times (volume ratio) of urea liquid;
(4) with above-mentioned through centrifugalize gained precipitate temperature be 1-10 ℃, concentration is 85% alcoholic solution flushing 2-3 time, the reuse temperature is 1-10 ℃, the alcohol flushing of concentration 100% one time afterwards, and airing, aseptic preservation promptly becomes the compound dosage form of bone morphogenetic protein of the present invention and hydroxyapatite.
2, manufacture method according to claim 1, its feature is 50-500 μ m in the granularity of hydroxyapatite.
CN98125670A 1998-12-21 1998-12-21 Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form Expired - Fee Related CN1087633C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98125670A CN1087633C (en) 1998-12-21 1998-12-21 Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98125670A CN1087633C (en) 1998-12-21 1998-12-21 Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form

Publications (2)

Publication Number Publication Date
CN1220168A true CN1220168A (en) 1999-06-23
CN1087633C CN1087633C (en) 2002-07-17

Family

ID=5229273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98125670A Expired - Fee Related CN1087633C (en) 1998-12-21 1998-12-21 Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form

Country Status (1)

Country Link
CN (1) CN1087633C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386742A (en) * 2019-08-14 2021-02-23 美迪帕克医疗器械有限公司 Bone graft composition, preparation method thereof and bone graft composition kit
CN112773935A (en) * 2020-03-31 2021-05-11 美迪帕克医疗器械有限公司 Bone graft composition and method for preparing the same
CN114471388A (en) * 2021-12-08 2022-05-13 大连民族大学 Preparation method of universally applicable hydrophobic shell gel particles

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100342923C (en) * 2002-09-30 2007-10-17 张余 Compound coral artificial bone suspension for injection and its prepn process
CN1329086C (en) * 2002-09-30 2007-08-01 尹庆水 Compound coral hydroxyapatite artificial bone and its prepn process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1031040C (en) * 1989-11-16 1996-02-21 齐齐哈尔轻工学院 Bioactive coating-titanium alloy artificial bone, artificial joint and preparation method
CN2183774Y (en) * 1994-05-03 1994-11-30 北京京航生物医学工程公司 Artificial joint with hydroxy apatite surface
CN1081072C (en) * 1997-11-19 2002-03-20 华南理工大学 Method for preparing artificial joint with bio-active gradient coating

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386742A (en) * 2019-08-14 2021-02-23 美迪帕克医疗器械有限公司 Bone graft composition, preparation method thereof and bone graft composition kit
US11918706B2 (en) 2019-08-14 2024-03-05 MedPark Co.,Ltd Composition for bone defect and preparation method of the same and kit for the same
CN112773935A (en) * 2020-03-31 2021-05-11 美迪帕克医疗器械有限公司 Bone graft composition and method for preparing the same
CN114471388A (en) * 2021-12-08 2022-05-13 大连民族大学 Preparation method of universally applicable hydrophobic shell gel particles

Also Published As

Publication number Publication date
CN1087633C (en) 2002-07-17

Similar Documents

Publication Publication Date Title
US4620327A (en) Process of adapting soluble bone protein for use in stimulating osteoinduction
US7132110B2 (en) Tissue repair compositions and methods for their manufacture and use
EP0795337B1 (en) A method of preparing biological implantation material
CA1272129A (en) Pharmaceutical depot compositions comprising natural bone mineral
EP0489728B1 (en) Chemical compounds
JP2009515611A (en) Bone repair material
US20130316012A1 (en) Method of Demineralizing Bone
EP1962716A2 (en) Porous calcium phosphate bone material
JPH01236058A (en) Bone restoration composition and method
US8752777B2 (en) Method and pulverizing apparatus for preparing pulverized product of extracted tooth, demineralized powder originated from extracted tooth, and composite of demineralized powder and apatite, suitable for use in highly advanced medical treatments
CN102138905B (en) RhBMP-2-loaded chitosan microspheres, preparation method thereof and application thereof
CN1087633C (en) Method for preparing bone morphogenesis protein and hydroxyapatite compound dosage form
US6830763B2 (en) Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby
EP1306390B1 (en) Method of producing low molecular weight chitin/chitosan and method of producing an osteoconduction substance
CN107496988B (en) Freeze-dried tooth bone powder material and preparation method thereof
CN102475916A (en) Preparation method of composite preparation of bone morphogenetic protein and hydroxyapatite
US20050064041A1 (en) Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby
DE60018607T2 (en) BONE-MAKING MATERIAL
CN116036377B (en) Preparation method of novel blocky heterogeneous bone repair material
JP4683694B2 (en) Method for producing absorbable biomaterial
CN1068198C (en) Production of composite preparation of bone morphogenesis protein and collagen particle
JP3981725B2 (en) Apatite hydrogel complexed with protein, solidified body thereof, and production method thereof
RU90322U1 (en) OSTEOPLASTY IMPLANT
CN116036377A (en) Preparation method of novel blocky heterogeneous bone repair material
JP3204567B2 (en) Dephosphorization of seawater

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee